Showing results (131-140 of 151) with videos related to

Sort By:
Pageof 16
Nano Letters|April 22, 2025
Direct cGAMP Delivery via Iron Oxide Nanoparticles for Enhanced STING Activation and Durable Antitumor ImmunityChen Yang, Han Ma, Junli Meng, et al.
National Science Review|February 9, 2026
Superparamagnetic iron oxide nanoparticle restores gut microbiota homeostasis to enhance lung cancer immunotherapyYayi He, Wengang Zhang, Zhanhang Guo, et al.
Translational Lung Cancer Research|April 11, 2022
Three-dimensionally printed navigational template: a promising guiding approach for lung biopsyHaoran E, Jiafei Chen, Weiyan Sun, et al.
Translational Lung Cancer Research|August 25, 2021
Risk-score model to predict prognosis of malignant airway obstruction after interventional bronchoscopyMinlin Jiang, Hao Xu, Dongmei Yu, et al.
Oncotargets and Therapy|May 12, 2021
Tumor Mutation Burden and Differentially Mutated Genes Among Immune Phenotypes in Patients with Lung AdenocarcinomaHao Wang, Shanhao Chen, Die Meng, et al.
Translational Lung Cancer Research|September 21, 2020
Predictive and prognostic significance of M descriptors of the 8th TNM classification for advanced NSCLC patients treated with immune checkpoint inhibitorsSangtian Liu, Fei Zhou, Zhiyu Liu, et al.
Lung Cancer (Amsterdam, Netherlands)|January 2, 2018
Characterization of never-smoking and its association with clinical outcomes in Chinese patients with small-cell lung cancerXiaozhen Liu, Tao Jiang, Wei Li, et al.
Translational Lung Cancer Research|July 17, 2025
A retrospective real-world single-arm study evaluating the efficacy and safety of neoadjuvant chemotherapy in patients with selected limited-stage small-cell lung cancerWengang Zhang, Yujie Li, Jing Nie, et al.
International Journal of Cancer|April 29, 2014
Epithelial phenotype as a predictive marker for response to EGFR-TKIs in non-small cell lung cancer patients with wild-type EGFRShengxiang Ren, Chunxia Su, Zhaoye Wang, et al.
Lung Cancer (Amsterdam, Netherlands)|May 12, 2018
EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphismSangtian Liu, Yayi He, Tao Jiang, et al.
Pageof 16